TP53 and breast carcinoma: These results suggest that, in contrast to its tumor-promoting role in the regulation of p53 activity, SIRT1 represses oncogenic estrogen signaling in breast cancer cells, both directly and indirectly, by deacetylating ERα and disrupting coactivator complex assembly.